Welcome to our dedicated page for Fresenius Med Cr SEC filings (Ticker: FMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Fresenius Medical Care AG (FMS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the New York Stock Exchange. Fresenius Medical Care files reports on Form 6-K under the Securities Exchange Act of 1934, furnishing press releases, financial figures, and other information that it discloses in its home market.
In these filings, investors can review quarterly financial updates that include revenue, operating income, net income, earnings per share, cash flow, and net leverage ratio, along with reconciliations of non-GAAP or non-IFRS measures such as EBITDA, free cash flow, and constant-currency results. The company’s 6-Ks also describe segment performance across Care Delivery, Care Enablement, and Value-Based Care, highlighting organic revenue growth, margins, and the impact of portfolio optimization and transformation programs like FME25+.
Fresenius Medical Care uses Form 6-K to furnish information on strategic initiatives and capital allocation decisions. Examples include disclosures related to its initial EUR 1 billion share buyback program, including tranches, timing, and regulatory notices furnished as convenience translations of European market abuse regulation disclosures. Filings may also reference bond issuances, debt redemption, and elements of the company’s capital structure.
Other 6-K submissions include press releases on leadership changes within the Management Board, updates on the FME Reignite strategy, and information about investments in entities such as Interwell Health. These documents help investors understand how Fresenius Medical Care manages its integrated dialysis business, transformation efforts, and value-based care activities.
On Stock Titan, SEC filings for FMS are supplemented with AI-powered summaries that highlight key figures, segment trends, and notable disclosures, helping users navigate lengthy documents more efficiently. Real-time updates from EDGAR ensure that new 6-Ks and other relevant filings appear promptly, while structured access to filings supports deeper analysis of Fresenius Medical Care’s financial performance, capital allocation, and strategic direction over time.
Fresenius Medical Care AG reports interim operating updates and segment changes. As of June 1, 2025, the company created a new Value‑Based Care segment, recognizing full‑risk arrangements under IFRS 17 with premiums and claim costs presented separately. For the nine months ended September 30, 2025, 16% of consolidated revenue was attributable to U.S. federally funded programs.
Capital efficiency remained modest: ROIC was 4.1%, or 4.9% excluding Legacy Portfolio Optimization costs, based on NOPAT of €1,101 M and average invested capital of €27,150 M. Total assets were €30,887 M and invested capital €25,471 M as of September 30, 2025.
Regulatory dynamics continue to influence U.S. operations. CMS proposed to terminate the mandatory ETC model on December 31, 2025; 971 U.S. facilities (about 35%) are currently in ETC regions and the program to date produced a net positive payment adjustment. The company participates in 21 KCEs, with approximately 52,000 patients aligned as of September 2025, reflecting scale in value‑based kidney care.
Fresenius Medical Care AG furnished a Form 6-K announcing its third quarter results for the period ended September 30, 2025. The submission includes a press release (Exhibit 99.1) and accompanying financial figures (Exhibit 99.2).
The company highlights non-GAAP measures alongside IFRS results, including EBITDA, free cash flow, net leverage ratio (net debt to adjusted EBITDA), constant-currency metrics, and results adjusted for special items, with reconciliations provided in the exhibits. The exhibits are furnished, not filed.
FAQ
What is the current stock price of Fresenius Med Cr (FMS)?
What is the market cap of Fresenius Med Cr (FMS)?
